Elevar's Lyrfigtu has been approved by the FDA for the treatment of bile duct cancer. The drug is a selective inhibitor of FGFR2, a receptor that can drive tumor growth.
The approval is notable as the first time a novel cancer drug from a Korean company has received FDA clearance. This marks a significant step for the Korean biotech industry, which has been expanding its global footprint.
Lyrfigtu offers a new therapeutic option for patients with bile duct cancer, a malignancy that often has limited treatment choices. The FDA's decision follows the drug's regulatory review for this indication.